C A Kruse

807 total citations
20 papers, 677 citations indexed

About

C A Kruse is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, C A Kruse has authored 20 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Immunology and 4 papers in Oncology. Recurrent topics in C A Kruse's work include Immunotherapy and Immune Responses (6 papers), CAR-T cell therapy research (3 papers) and Immune Cell Function and Interaction (3 papers). C A Kruse is often cited by papers focused on Immunotherapy and Immune Responses (6 papers), CAR-T cell therapy research (3 papers) and Immune Cell Function and Interaction (3 papers). C A Kruse collaborates with scholars based in United States, Australia and Germany. C A Kruse's co-authors include Kevin O. Lillehei, Dawn H. Mitchell, John C. Stears, German G. Gomez, Francis Burrows, Geoffrey C. Owens, Michael E. Berens, Ruth J. Muschel, Martin Sattler and Hans‐Martin Schiebel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Infection and Immunity and Neurosurgery.

In The Last Decade

C A Kruse

20 papers receiving 652 citations

Peers

Countries citing papers authored by C A Kruse

Since Specialization

Citations

This map shows the geographic impact of C A Kruse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C A Kruse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C A Kruse more than expected).

Fields of papers citing papers by C A Kruse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C A Kruse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C A Kruse. The network helps show where C A Kruse may publish in the future.

Co-authorship network of co-authors of C A Kruse

This figure shows the co-authorship network connecting the top 25 collaborators of C A Kruse. A scholar is included among the top collaborators of C A Kruse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C A Kruse. C A Kruse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment 2014 ·Neuroimmunology and Neuroinflammation ·C A Kruse, (unknown), (unknown), Joseph Antonios, (unknown), Noriyuki Kasahara, Horacio Soto, (unknown)	33
2	The Potential for Genetically Altered Microglia to Influence Glioma Treatment 2013 ·CNS & Neurological Disorders - Drug Targets ·(unknown), R. M. Damian Holsinger, C A Kruse, Alexander Flügel, Manuel B. Graeber	13
3	Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells 2010 ·Anti-Cancer Agents in Medicinal Chemistry ·Florence M. Hofman, (unknown), C A Kruse, (unknown), Virgil E.J.C. Schijns	19
4	Permanent, Lowered HLA Class I Expression Using Lentivirus Vectors With shRNA Constructs: Averting Cytotoxicity by Alloreactive T Lymphocytes 2006 ·Transplantation Proceedings ·(unknown), Nathan A. Lemp, Christopher R. Logg, (unknown), (unknown), German G. Gomez, C A Kruse, Robert Mendez, Renata Stripecke, Noriyuki Kasahara, J Cicciarelli	25
5	X-ray microbeams: Tumor therapy and central nervous system research 2005 ·Nuclear Instruments and Methods in Physics Research Section A Accelerators Spectrometers Detectors and Associated Equipment ·F. Avraham Dilmanian, Yun Qu, Sheng Liu, Carlyne D. Cool, (unknown), James F. Hainfeld, C A Kruse, John Laterra, Daniel J. Lenihan, Marta M. Nawrocky, George D. Pappas, Chun‐I Sze, Tetsuya Yuasa, Nan Zhong, Z. Zhong, John W. McDonald	51
6	Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. 2003 ·PubMed ·(unknown), (unknown), Francis Burrows, C A Kruse	51
7	Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer 2001 ·Cancer Treatment Reviews ·German G. Gomez, (unknown), C A Kruse	32
8	Overexpression of a transmembrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma. 1998 ·PubMed ·Geoffrey C. Owens, (unknown), (unknown), Ruth J. Muschel, Michael E. Berens, C A Kruse	60
9	Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 1997 ·Cancer Immunology Immunotherapy ·C A Kruse, (unknown), (unknown), (unknown), John C. Stears, Kevin O. Lillehei	114
10	Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. 1997 ·PubMed ·C A Kruse, (unknown)	16
11	CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans 1996 ·Infection and Immunity ·Matthew B. Purner, Randolph L. Berens, Paul B. Nash, Annemie Van der Linden, Ewan A. Ross, C A Kruse, E C Krug, Tyler J. Curiel	41
12	Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. 1992 ·Drug Metabolism and Disposition ·Uwe Christians, Martin Sattler, Hans‐Martin Schiebel, C A Kruse, Heinfried H. Radeke, A Linck, K.‐Fr. Sewing	59
13	Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy 1991 ·Neurosurgery ·Kevin O. Lillehei, Dawn H. Mitchell, (unknown), (unknown), C A Kruse	90
14	Bioactivity of electric field-pulsed human recombinant interleukin-2 and its encapsulation into erythrocyte carriers. 1990 ·PubMed ·Dawn H. Mitchell, (unknown), C A Kruse	18
15	Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. 1990 ·Proceedings of the National Academy of Sciences ·C A Kruse, Kevin O. Lillehei, Dawn H. Mitchell, Bette K. Kleinschmidt‐DeMasters, Donald Bellgrau	37
16	[Bilateral and familial occurrence of germ cell tumors of the testis]. 1987 ·PubMed ·C A Kruse	6
17	Methotrexate loaded erythrocyte carriers optimizing their formation their characterization and their pharmacological efficacy in treating hepatoma 129 ascites tumors in mice 1987 ·C A Kruse, (unknown), (unknown), (unknown)	6
18	[Amyloid tumor of bone]. 1987 ·PubMed ·C A Kruse, (unknown)	1
19	[Histological classification and biological behavior of germ cell tumors of the testis. Studies based on surgery and autopsy data 1958-1979]. 1984 ·PubMed ·C A Kruse, Günther Wittstock	1
20	Stability of erythrocyte ghosts: a gamma-ray perturbed angular correlation study. 1983 ·Proceedings of the National Academy of Sciences ·C A Kruse, George W. Tin, John D. Baldeschwieler	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact